|
January 19, 2006 Categories: Uncategorized Posted by admin
Abbott Laboratories Inc.’s pivotal role in Boston Scientific Corp.’s $80-per-share offer to buy Guidant Corp. signals its determination to be a player in medical devices, regardless of how the bidding match ends, analysts said on Wednesday.
While many Wall Street analysts say Boston Scientific now has the upper hand over Johnson & Johnson with its current bid for Guidant, some believe Abbott’s participation — providing some of the funding for the bid — suggests Abbott could move in to buy Boston Scientific if it ultimately loses.
Full news
|
|
